
By Sneha S K and Sriparna Roy
(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is made in the next four months.
In a second letter to Novavax's board in less than a month, shared exclusively with Reuters on Wednesday, Shah Capital said it has become "increasingly disenchanted" with the company's weak COVID-19 vaccine sales.
"If I don't see changes happening, and if the company doesn't follow through in the next four months, then I think that is definitely a potential for a proxy fight," hedge fund founder Himanshu Shah said in an interview.
The fund said it still believes in Novavax's science and has increased its stake to about 8.3%, up from 7.2% in October.
However, it said it remains "at a complete loss" over the disappointing sales of Novavax's protein-based COVID-19 vaccine and is frustrated by its negligible market share.
DISCONNECT BETWEEN POTENTIAL AND EXECUTION
This marks another push from the activist investor for change after it withdrew a campaign against three board directors last year, following Novavax's licensing deal with Sanofi.
"It is reasonable to question whether Novavax and its partner are exhibiting a profound lack of competence or intentionally underperforming," the letter said.
Novavax's vaccine sold about 120,000 doses as of October 31, during the 2025-26 season that started in August, versus 14.5 million doses sold in the same period by two competitors, leaving Novavax's market share at about 0.8%, the letter said.
"Despite strong underlying science and evident market need, the disconnect between potential and execution is striking," the hedge fund said in its letter.
Earlier this month, Novavax pushed back its profitability target by a year to 2028.
Novavax has a high cost base, needs to be operationally profitable next year and should run more comprehensive trials, Shah said.
Shah values the company at $5 billion to $10 billion. Novavax's market capitalization is about $1.21 billion, according to LSEG data.
The fund urged the board to immediately form a committee to evaluate a sale and hire a qualified investment bank.
Shah has previously named Sanofi, Merck, GSK and AstraZeneca as potential buyers, but said he has not contacted them.
(Reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
LATEST POSTS
- 1
James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise - 2
Treasure trove found in Egyptian tomb solves ancient mystery - 3
Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand. - 4
AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets - 5
Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
Underestimated Metropolitan Experience Urban communities On the planet
Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
Your big brain makes you human – count your neurons when you count your blessings
RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
New movies to watch this weekend: See 'The Drama' in theaters, rent 'Wuthering Heights,' stream 'Pizza Movie' on Hulu












